Stock Chart
PRAX
Type: SELL wallstreet
Strike: $460
Premium: $45.00
Expiry: Jan 15, 2027
Target: $463
Score: -94
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About PRAX - Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Key Statistics
More PRAX Analysis
This PRAX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track PRAX's price movements with trendlines, gamma walls, and key support/resistance levels.